Zoetis Inc. or Insmed Incorporated: Who Manages SG&A Costs Better?

SG&A Cost Management: Zoetis Inc. vs. Insmed Incorporated

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Zoetis Inc. and Insmed Incorporated have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Zoetis Inc. consistently reported higher SG&A expenses, peaking at approximately $2.15 billion in 2023. In contrast, Insmed Incorporated's SG&A expenses grew from $31 million in 2014 to $345 million in 2023, reflecting a more than tenfold increase.

Despite Zoetis Inc.'s larger absolute figures, their expenses grew at a slower rate, indicating a more stable cost management strategy. Meanwhile, Insmed's rapid increase suggests aggressive expansion or investment in administrative capabilities. Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies.